R1 RCM Inc (NASDAQ:RCM) has received a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.

Brokers have set a 1-year consensus price target of $5.00 for the company and are anticipating that the company will post $0.02 EPS for the current quarter, according to Zacks. Zacks has also assigned R1 RCM an industry rank of 93 out of 265 based on the ratings given to its competitors.

A number of brokerages have recently issued reports on RCM. BidaskClub upgraded R1 RCM from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Zacks Investment Research downgraded R1 RCM from a “hold” rating to a “sell” rating in a report on Wednesday, January 17th.

Large investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new position in shares of R1 RCM in the 4th quarter valued at $112,000. Virtu Financial LLC purchased a new position in shares of R1 RCM in the 4th quarter valued at $166,000. Voya Investment Management LLC purchased a new position in shares of R1 RCM in the 2nd quarter valued at $170,000. Virtu KCG Holdings LLC increased its holdings in shares of R1 RCM by 291.3% in the 2nd quarter. Virtu KCG Holdings LLC now owns 56,000 shares of the financial services provider’s stock valued at $210,000 after acquiring an additional 41,690 shares during the period. Finally, Nationwide Fund Advisors purchased a new position in shares of R1 RCM in the 2nd quarter valued at $215,000. Institutional investors and hedge funds own 47.77% of the company’s stock.

R1 RCM (RCM) opened at $4.68 on Tuesday. The company has a market capitalization of $509.25, a price-to-earnings ratio of -18.00 and a beta of -0.41. R1 RCM has a fifty-two week low of $2.02 and a fifty-two week high of $5.43.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2018/02/13/zacks-r1-rcm-inc-rcm-given-consensus-recommendation-of-buy-by-brokerages.html.

R1 RCM Company Profile

R1 RCM Inc, formerly Accretive Health, Inc, is a provider of revenue cycle management (RCM) and physician advisory services (PAS) to healthcare providers. The Company is engaged in providing management services of revenue cycle operations for the United States-based hospitals and other medical services providers.

Get a free copy of the Zacks research report on R1 RCM (RCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.